Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind comparison of QL2302 versus Tezspire in uncontrolled severe adult asthma
CTR20254686Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tezepelumab in severe asthma, sponsored by Qilu Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on CTR20254686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254686.